Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Mavacamten 15mg vs 3x5mg in Healthy Participants
NCT05362045Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mavacamten in hypertrophic cardiomyopathy (HCM) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration at 1 month, Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration at 1 month and 1 more. Started May 2022; status: completed.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT05362045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05362045.